threewheeler
12 hours ago
KRTL Holding Group Reports 2024 Financial Results and Advances Toward International Pharmaceutical Integration
Press Release | 03/31/2025
KRTL Holding Group, Inc. (OTC: KRTL), a diversified holding company with subsidiaries engaged in pharmaceutical consulting, regulatory compliance, and international commercialization, today reported its financial results for the year ended December 31, 2024, and outlined its strategic roadmap for 2025.
Operational & Strategic Milestones
Strategic Merger Initiated: KRTL Biotech signed a Memorandum of Understanding (MOU) with Bolivia-based Industria QuÃ?Âmico FarmacÃ?©utica Sigma Corp. S.R.L., initiating a formal international merger process and integrated manufacturing expansion.
Regulatory Compliance Strengthened: Maintained FDA registration for KRTL Biotech's operational platform and implemented a robust Quality Management System (QMS), aligning with international regulatory standards.
Market Expansion Efforts: Attracted interest from U.S. and South American pharmaceutical manufacturers seeking entry to the U.S. via KRTL Biotech's compliance infrastructure for faster, regulation-aligned distribution.
Enhanced Internal Capabilities: Expanded internal teams in legal, accounting, and strategic advisory to support governance, licensing, and market entry advisory services.
Looking Ahead � KRTL Strengthens Global Infrastructure
In 2025, KRTL continues to evolve with international production capabilities and scalable regulatory support. The Company's FDA-anchored regulatory foundation, expanding QMS, and growing pharmaceutical network position it to offer high-value services and products, including:
U.S. Market Entry Support: Assisting foreign manufacturers in leveraging KRTL's FDA-registered subsidiary and quality systems for streamlined entry into the U.S. market.
API Sourcing and Oversight: Managing formulation, labeling, and sourcing in partnership with GMP-certified manufacturers in the U.S. and South America, supported by bilateral logistics frameworks and FDA documentation protocols.
Regulatory Consulting & Licensing: Providing strategic regulatory guidance and licensing support to early-stage pharmaceutical and nutraceutical companies, ensuring 21 CFR, DEA, and international compliance alignment.
Revenue-Sharing & Commercialization: Facilitating product commercialization and revenue-sharing partnerships under the KRTL umbrella, including current product launches and licensing structures.
CEO Cesar Herrera commented: "KRTL is creating new opportunities for partners, international consultants, and global investors by actively identifying undervalued assets and leveraging the company's expertise in regulatory and operational frameworks. The company continues to pursue mergers and acquisitions, strategically evaluating and stacking candidates that align with its long-term growth vision. Recent achievements, including FDA registration, implementation of a Quality Management System (QMS), and the merger with SIGMA, validate KRTL's unique infrastructure, which enables scalable compliance, robust revenue generation, and expanded access to global markets. We expect 2025 to be a transformative year for the company."
2024 Financial Highlights
Net Income: Achieved net income of $887,587, compared to a net loss of $71,077 in 2023.
Earnings Per Share (EPS): Reported EPS of $0.01 for 2024, versus $0.00 in the prior year.
Non-Cash Revenue: Recognized non-cash revenue of $2.6 million for services provided in exchange for marketable securities.
Investment Asset Growth: Increased investment asset value to $1.54 million at year-end 2024, up from $380,000 in 2023.
Capital Structure: Maintained a streamlined capital structure with 87.2 million shares of common stock issued and outstanding.
This financial turnaround reflects early gains from cross-border licensing strategy, regulatory platform scalability, and international manufacturing synergies.
For additional disclosure
Please refer to the Annual Report for the year ended December 31, 2024, filed on otcmarkets.com/KRTL.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
PrivateEquity
13 hours ago
Great earnings report for $KRTL!
Net Income: Achieved net income of $887,587, compared to a net loss of $71,077 in 2023.
KRTL Holding Group, Inc. (OTC: KRTL), a diversified holding company with subsidiaries engaged in pharmaceutical consulting, regulatory compliance, and international commercialization, today reported its financial results for the year ended December 31, 2024, and outlined its strategic roadmap for 2025.
Operational & Strategic Milestones
Strategic Merger Initiated: KRTL Biotech signed a Memorandum of Understanding (MOU) with Bolivia-based Sigma Corp. S.R.L., initiating a formal international merger process and integrated manufacturing expansion.
Regulatory Compliance Strengthened: Maintained FDA registration for KRTL Biotech's operational platform and implemented a robust Quality Management System (QMS), aligning with international regulatory standards.
Market Expansion Efforts: Attracted interest from U.S. and South American pharmaceutical manufacturers seeking entry to the U.S. via KRTL Biotech's compliance infrastructure for faster, regulation-aligned distribution.
Enhanced Internal Capabilities: Expanded internal teams in legal, accounting, and strategic advisory to support governance, licensing, and market entry advisory services.
Looking Ahead KRTL Strengthens Global Infrastructure
In 2025, KRTL continues to evolve with international production capabilities and scalable regulatory support. The Company's FDA-anchored regulatory foundation, expanding QMS, and growing pharmaceutical network position it to offer high-value services and products, including:
U.S. Market Entry Support: Assisting foreign manufacturers in leveraging KRTL's FDA-registered subsidiary and quality systems for streamlined entry into the U.S. market.
API Sourcing and Oversight: Managing formulation, labeling, and sourcing in partnership with GMP-certified manufacturers in the U.S. and South America, supported by bilateral logistics frameworks and FDA documentation protocols.
Regulatory Consulting & Licensing: Providing strategic regulatory guidance and licensing support to early-stage pharmaceutical and nutraceutical companies, ensuring 21 CFR, DEA, and international compliance alignment.
Revenue-Sharing & Commercialization: Facilitating product commercialization and revenue-sharing partnerships under the KRTL umbrella, including current product launches and licensing structures.
CEO Cesar Herrera commented: "KRTL is creating new opportunities for partners, international consultants, and global investors by actively identifying undervalued assets and leveraging the company's expertise in regulatory and operational frameworks. The company continues to pursue mergers and acquisitions, strategically evaluating and stacking candidates that align with its long-term growth vision. Recent achievements, including FDA registration, implementation of a Quality Management System (QMS), and the merger with SIGMA, validate KRTL's unique infrastructure, which enables scalable compliance, robust revenue generation, and expanded access to global markets. We expect 2025 to be a transformative year for the company."
2024 Financial Highlights
Net Income: Achieved net income of $887,587, compared to a net loss of $71,077 in 2023.
Earnings Per Share (EPS): Reported EPS of $0.01 for 2024, versus $0.00 in the prior year.
Non-Cash Revenue: Recognized non-cash revenue of $2.6 million for services provided in exchange for marketable securities.
Investment Asset Growth: Increased investment asset value to $1.54 million at year-end 2024, up from $380,000 in 2023.
Capital Structure: Maintained a streamlined capital structure with 87.2 million shares of common stock issued and outstanding.
This financial turnaround reflects early gains from cross-border licensing strategy, regulatory platform scalability, and international manufacturing synergies.
threewheeler
1 day ago
KRTLBIOTECH OTC:KRTL
@KRTLBiotech
Attention $KRTL Shareholders:
Management is pleased to announce that multiple press releases are currently in preparation. We continue to make solid progress toward our strategic goals, including the evaluation and execution of merger and stacking opportunities. These moves are designed to unlock arbitrage potential and enhance shareholder value.
Financials completed ☑️, being reviewed!
12:41 PM · Mar 28, 2025
·
1,685 Views $KRTL, is about to make a move up again!!!
This Monday KRTL will post year-end earnings report and 2024 Annual Report. I don't foresee any surprises in it.
This Tuesday KRTL starts to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream on Wednesday April 2, 2025, at 10:00am ET under the ticker symbol "KRTL".
Cesar Herrera, CEO of KRTL, commented, Many stakeholders, especially in South America, have asked how they can invest in our company, and now they can simply download the Upstream app and start trading.
On March 24, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL), a diversified holding company operating through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp., is pleased to announce that its wholly owned subsidiary, KRTL Biotech Inc., has signed a Memorandum of Understanding (MOU) with Industria Químico Farmacéutica Sigma Corp. S.R.L. ("Sigma") of Bolivia. This MOU establishes the framework for a strategic international merger between the two pharmaceutical entities.
Rattlershehe
2 days ago
Hello Everyone,
$KRTL, is about to make a move up again!!!
This Monday KRTL will post year-end earnings report and 2024 Annual Report. I don't foresee any surprises in it.
This Tuesday KRTL starts to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading becomes available on Upstream on Wednesday April 2, 2025, at 10:00am ET under the ticker symbol "KRTL".
Cesar Herrera, CEO of KRTL, commented, Many stakeholders, especially in South America, have asked how they can invest in our company, and now they can simply download the Upstream app and start trading.
On March 24, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL), a diversified holding company operating through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp., is pleased to announce that its wholly owned subsidiary, KRTL Biotech Inc., has signed a Memorandum of Understanding (MOU) with Industria Químico Farmacéutica Sigma Corp. S.R.L. ("Sigma") of Bolivia. This MOU establishes the framework for a strategic international merger between the two pharmaceutical entities.
KRTL could go well above $25 a share within six months of just that one merger…
I have spoke about KRTL many times, do your DD’s. If you have any questions just ask.
KRTL The Golden Ticket
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Ask ADVFN Intelligence (AI)
Landwehr
9 hours ago
stealofadeal
12 hours ago
bluebird50
3 days ago
ProfitChaser
6 days ago
TimeIsFading
6 days ago
